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IRF4 Gene Rearrangements Define a Subgroup of
CD30-Positive Cutaneous T-Cell Lymphoma:
A Study of 54 Cases
Anne Pham-Ledard1, Martina Prochazkova-Carlotti1, Elodie Laharanne1, Be´atrice Vergier2, Thomas Jouary3,
Marie Beylot-Barry1,4 and Jean-Philippe Merlio1,2
The identification of IFN regulatory factor 4 gene (IRF4) translocation in 8 out of 14 cases of cutaneous ana-
plastic large cell lymphomas (C-ALCLs) (Leukemia, 2009; 23(3):574–80) prompted us to study IRF4 locus status
in different cutaneous T-cell lymphoma (CTCL) subtypes. Fluorescence in situ hybridization (FISH) was used
with break-apart dual-color probes. Sixty samples from 54 patients were analyzed with 23 C-ALCL,
11 transformed mycosis fungoides (T-MF), 7 lymphomatoid papulosis (LyP), and 13 Se´zary syndrome (SS)
cases. IRF4 immunostaining was performed in 32 cases. We observed a split FISH signal pattern indicating
a translocation at the IRF4 locus in 6 out of 23 C-ALCL (26%) and 2 out of 11 T-MF (18.2%) cases. Extra copies
of the IRF4 locus were found in 4 out of 13 SS, 1 out of 11 T-MF, and 1 out of 23 C-ALCL cases, corresponding
to either aneuploidy, chromosome 6 trisomy, or 6p partial gain. The IRF4 expression was not correlated with
the presence of IRF4 alteration in C-ALCL or T-MF. Interestingly, IRF4 rearrangements define a subgroup
of CD30-positive C-ALCL and T-MF cases. Conversely, T-MF cases with IRF4 rearrangements may correspond
to the development of C-ALCL in MF patients and not to large cell transformation. Investigation of the bio-
logical pathways triggered by IRF4 rearrangements and/or expression in CTCL will provide a biological basis
for IRF4-directed therapy.
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INTRODUCTION
The IFN regulatory factor 4 gene (IRF4), also known as
multiple myeloma (MM) antigen 1 (MUM1), is normally
expressed in plasma cells, melanocytes, some B cells, and in
activated T cells (Falini et al., 2000). The IRF4 protein is
required at several stages of B-cell development, including in
the differentiation of mature B cell into antibody-secreting
plasma cells (Lu, 2008), and is also critical for Th2 and Th17
T-cell differentiation (Brustle et al., 2007; Zheng et al., 2009)
and T-cell cytotoxic function (Mittrucker et al., 1997). In
some MM cases, IRF4 is involved in t(6;14)(p25;q32)
reciprocal translocation and is juxtaposed with the
immunoglobulin heavy chain (IGH) gene locus, leading to
an IRF4 deregulated expression (Iida et al., 1997; Yoshida
et al., 1999; Shaffer et al., 2008). IRF4 rearrangements
have also been described in rare cases of diffuse large cell
B-cell lymphomas (Tamura et al., 2001), splenic marginal
zone lymphoma (Remstein et al., 2008), and chronic B-cell
lymphoid leukemia (Michaux et al., 2005).
As a matter of fact, Feldman et al. (2009) recently detected
a recurrent translocation involving the 6p25.3 locus in
peripheral T-cell lymphomas (PTCLs), suggesting an IRF4
rearrangement. Among 169 PTCL cases, they identified 12
patients with IRF4 locus rearrangements, with 8 cases
corresponding to cutaneous CD30-positive anaplastic large
cell lymphoma (C-ALCL). Moreover, extra-cutaneous lymph
node spreading was observed in four of these eight cases and
only in one out of six cases with a normal IRF4 status,
suggesting that the rearrangements confer clinical aggres-
siveness. In addition, Feldman et al. (2009) showed a
reciprocal translocation between the IRF4 and the TCR-a
locus in two CD30-negative PTCL cases, but neither in C-
ALCL cases nor in two other systemic PTCL (one PTCL not
otherwise specified and one systemic anaplastic lymphoma
kinase (ALK)-negative ALCL) cases.
The presence of IRF4 rearrangements has not been
studied in other types of cutaneous lymphoproliferations
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such as mycosis fungoides (MF), Se´zary syndrome (SS), and
lymphomatoid papulosis (LyP). MF, the most common
cutaneous T-cell lymphoma (CTCL) (50% of cases), is an
indolent disease with cutaneous patches or plaques in
patients at an early tumor node metastasis stage (Olsen
et al., 2007). The development of skin tumor with epidermo-
tropism loss and large cell transformation (transformed
mycosis fungoide, T-MF) represents a turning point in about
20% of patients with MF and a median survival of 1–2 years
(Diamandidou et al., 1998). In contrast to MF, SS is a de novo
aggressive epidermotropic CTCL defined by a triad of
erythroderma, generalized lymphadenopathy, and the pre-
sence of atypical or neoplastic T cells (Se´zary cells) in
peripheral blood (Willemze et al., 2005).
Primary cutaneous CD30-positive lymphoproliferative
disorders (30% of CTCL) include C-ALCL, LyP, and borderline
cases. LyP is considered to be a chronic, recurrent,
self-healing papulonecrotic, or papulonodular skin disease
(Willemze et al., 2005). C-ALCL mainly affects adults with
solitary cutaneous nodules or tumors characterized by
abundant sheets of CD30-positive anaplastic cells in the
dermis (more than 75% of tumor cells) (Willemze et al.,
2005). However, some LyP lesions display histological
features of C-ALCL. On the other hand, C-ALCL is sometimes
multifocal (20% cases), and a partial or complete sponta-
neous regression of skin lesions is observed in about 40% of
patients, as well as cutaneous relapse (Bekkenk et al., 2000).
Unlike systemic CD30-positive ALCL or T-MF, the prognosis
of C-ALCL is excellent, with a 10-year survival of over 90%
(Willemze et al., 2005). Extracutaneous spread occurs in only
10% of cases, but when limited to the draining regional
lymph node, such progression does not seem to alter
prognosis (Bekkenk et al., 2000). Whether IRF4 rearrange-
ments could be a diagnostic or predictive marker for CD30þ
cutaneous lymphoproliferations has not been determined.
Indeed, LyP can be preceded by, associated with, or followed
by another type of malignant cutaneous lymphoma in the same
patient, generally MF, C-ALCL, or Hodgkin’s lymphoma. More-
over, some cases of T-MF exhibit skin lesions with abundant
CD30-positive large or anaplastic cells in the dermis, and the
differential diagnosis between large cell transformation of MF or
association with C-ALCL in the same patient may have important
therapeutic and prognostic consequences.
The value of several phenotypical markers for such a
purpose has been evaluated. Kempf et al. (2008) reported that
IRF4 expression may be a valuable tool for the distinction
between LyP and C-ALCL. This result was not confirmed by
other groups (Wasco et al., 2008; Hernandez-Machin et al.,
2009). A recent study of TRAF1, MUM1, BCL2, and CD15
expression did not identify a specific signature for each
cutaneous CD30-positive lymphoproliferative disorder
(Benner et al., 2009).
The aim of our study was to first analyze whether IRF4
rearrangements could be detected in specific types of CTCL
expressing the CD30 antigen, including C-ALCL, LyP, and
T-MF cases. We also investigated whether CD30-negative
T-MF and SS cases could bear IRF4 rearrangements. We
developed a split signal or break-apart dual-color DNA probe
fluorescence in situ hybridization (FISH) assay that is
applicable to different sources of diagnostic material such
as isolated nuclei, formalin-fixed paraffin-embedded (FFPE)
sections, fresh/frozen tissue touch imprints, or cytogenetic
preparations. We also studied IRF4 protein expression by
immunohistochemistry to evaluate whether cases with IRF4
rearrangements could be identified by a higher level of
immunoreactivity. Finally, we tried to determine whether
cases with IRF4 rearrangements display specific clinical or
evolutive features.
RESULTS
Patients and samples
Sixty-seven samples were analyzed by FISH corresponding to
skin (n¼ 49, 7Ly, 11 T-MF and 31 C-ALCL), blood (n¼13, 13
SS), node (n¼4, 4 C-ALCL), or bone marrow (n¼1, 1 T-MF)
material. Sixty samples were informative and matched to 54
patients: 23 C-ALCL, 11 T-MF, 13 SS, and 7 LyP. Patients
presented with either C-ALCL alone (n¼18), C-ALCL with
regional lymph node involvement at the time of sampling
(n¼5), T-MF (n¼11), de novo SS (n¼10), or secondary SS
(n¼3) (SS preceded by T-MF). Among the 11 patients with
T-MF, 8 were CD30 positive (more than 50% of large cells)
and 3 were CD30 negative.
6p25-specific locus FISH analysis
We observed three types of FISH pattern (Figure 1): normal
pattern with two fusions (2F) (Figure 3d); split patterns with
one fusion, one red, one green (1F-1R-1G), or 2Fþ1G extra
signal (Figure 2a); and extra copies pattern of nonrearranged
IRF4 locus (more than 2F) (Figures 1b, 2b and c). As
summarized in Table 1, we observed a normal FISH pattern
in 40 patients (74%). A monoallelic split pattern suggesting
IRF4 translocation was found in 8 out of 54 patients (14.8%)
and extra copies of the IRF4 locus were observed in 6 out of
54 cases (11.2%). All cases exhibiting an IRF4 abnormal
pattern are presented in Table 2.
IRF4 locus rearrangements
Among 54 CTCLs, we identified 8 CTCLs (14.8%) with a split
signal pattern (Figure 2a) suggesting an IRF4 break point: 6
out of 23 C-ALCLs (26%) and 2 out of 11 T-MF (18.2%). The
percentages of nuclei with split signal ranged from 31 to 88%
(Tables 1 and 2).
In most cases (6 of 8), the split signal was 1F-1R-1G, with a
break point lying between the 30 end of CTD-2308G5 and the
50 end of RP11-164H16 BAC probes, suggesting the existence
of a major breakpoint region, spanning almost 130 kb. Two
patients carrying rearrangements (one C-ALCL and one T-MF,
cases 1 and 8, Table 2) showed a particular FISH pattern: A
2F signal with a green extra signal, indicating that the break
point maps within the region hybridizing to the 30 IRF4-
flanking BAC probe (RP11-164H16). In case 1, FISH analysis
was also performed on skin tumor cell metaphases. In this
sample, the 30 IRF4-flanking probe extra signal was observed
on 6q (Figure 2d–f), in accordance with the previously
published G-banded tumor karyotype of skin tumor cells
showing inv(6)(p23;q15) (Chevret et al., 2006). Interestingly,
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the two T-MF cases with IRF4 rearrangements were CD30
positive, whereas no split was observed in CD30-negative
T-MF, SS, or LyP cases.
Probe validation on metaphases from healthy cells was
performed as a prerequisite before patient analysis. Because
of false-positive extra signals corresponding to nonspecific
hybridization 16p of BAC clones RP11-119L15, CTD-
2314K17, and CTD-3052J12 these probes were discarded.
Extra copies of nonrearranged 6p25 or IRF4 locus
Extra copies of the IRF4 locus without a split signal were
found in 4 out of 13 SS (30.8%), 1 out of 11 T-MF (9.9%), and
1 out of 23 C-ALCL (4.3%) cases (Table 1). In 13 SS cases
analyzed on cytogenetic preparations obtained from blood
samples, three exhibited a three fusion (3F) signal pattern
(Figure 2b), suggesting either a gain of one IRF4 locus or
chromosome 6 trisomy. One T-MF case also exhibited such a
signal pattern (3F), and one C-ALCL showed four fusion (4F)
signals. We did not detect any extra copies of the IRF4 locus
in LyP cases. Furthermore, no signal loss of the IRF4 locus
was observed both in cases with or without an IRF4
rearrangement, indicating that IRF4 rearrangements are
balanced and more generally the absence of IRF4 deletion.
Clinical data
Among six C-ALCL cases carrying IRF4 rearrangements, two
patients had node involvement at the time of biological
sampling, and two other patients had a cutaneous relapse
during follow-up. None of these patients had lymph node
involvement after follow-up; and all are alive with complete
remission. Conversely, three patients without IRF4 rearrange-
ments had lymph node involvement at the time of the study
and three other patients without an IRf4 rearrangement had
regional node progression (data not shown).
FISH combined with immunofluorescence
Skin sections of three C-ALCL cases with IRF4 break point
were analyzed by FISH, combined with immunofluorescence
(IRF4 locus-specific FISH, followed by CD30 immunostain-
ing). In case 1, 100 cells were analyzed and 74% were found
to be CD30 positive (Figure 2g and h). Eighty-three percent of
cells expressing the CD30 antigen also exhibited a split signal
pattern, indicating an IRF4 locus translocation, and none of
the CD30 negative cells harbored an IRF4 break point (Figure
2h). We also detected CD30-positive cells (17%) that
displayed a normal FISH pattern (Figure 2i). Similar results
were found in two other patients (cases 3 and 4) but only 24
and 17 cells, respectively, could be analyzed. Altogether,
FISH, followed by immunofluorescence, showed that most
CD30-positive cells exhibited an IRF4 rearrangement, but a
subset of CD30-positive cells had a normal FISH pattern.
IRF4 or MUM1 immunostaining
Different CTCL subtypes were found to express the IRF4
protein, although at variable levels, as shown in Table 3 and
Figure 3. However, no difference in IRF4 immunostaining
was observed between C-ALCL, LyP, and T-MF subgroups.
All C-ALCL cases with an IRF4 locus rearrangement showed
IRF4 expression (six of six), but one out of two T-MF cases
carrying the IRF4 break point showed IRF4 protein expression
in only 10–50% of tumor cells. IRF4 immunostaining was
found in485% of tumor cells in four C-ALCL cases with IRF4
rearrangement, the two others showed IRF4 expression in
50–85% of tumor cells. Nevertheless, IRF4 immunostaining
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Figure 1. IRF4 locus-specific fluorescence in situ hybridization (FISH) strategy. (a) Schematic representation of all BAC clones hybridizing to the 6p25 region
used in this study. RP11-119L15, CTD-2317K17, and CTD-3052J12 BAC clones, which showed nonspecific hybridization on chromosome 16, were discarded.
The break-apart BAC probe strategy used CTD-2308G5 as the 50 IRF4 BAC probe and RP11-164H16 as the 30 IRF4 BAC probe. (b) The FISH signal pattern
expected in interphase nuclei samples. Normal nuclei would exhibit a two-fusion (2F) signal pattern corresponding to the juxtaposition of BAC clones probes.
Nuclei with an IRF4 locus break point, suggesting translocation, would show a split signal pattern (1F-1R-1G). Nuclei with extra copies of a
non-rearranged IRF4 locus should exhibit more than a 2F signal pattern.
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was not correlated with IRF4 locus status as determined by
FISH: 23 out of 24 patients (12 C-ALCL, 7 LyP, 4 T-MF)
without an IRF4 genomic abnormality were found positive
(more than 10% of cells). Furthermore, in LyP cases, IRF4 was
expressed by485% of CD30-positive large cells in six out of
seven cases.
Array-CGH profile
The chromosome 6 array-CGH profile was determined for 11
patients with C-ALCL, for 7 patients with T-MF, as well as for
11 patients with SS. Eight of these patients were found to
exhibit an IRF4 locus abnormality (Table 2). However, the
array-CGH profile did not show any specific IRF4 or
chromosome 6p imbalance in cases with (n¼5, 4 C-ALCL
and 1 T-MF) or without (n¼24) an IRF4 break point. In one
SS case (case 11) with one extra copy of the IRF4 locus, as
determined by FISH (3F detected in 90% nuclei analyzed),
the array-CGH profile showed a 6p22–p25 gain, encompass-
ing the IRF4 locus. In two other patients with SS (cases 12 and
14), extra copies of the IRF4 locus were detected by FISH in
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Figure 2. IRF4 locus-specific fluorescence in situ hybridization (FISH) analysis. (a) Interphase FISH. Isolated nuclei obtained from formalin-fixed, paraffin-
embedded (FFPE) skin sample of case 5. SpectrumGreen-labeled 50 IRF4 probe and Cyanine3-labeled 30 IRF4 probe shows 1F-1R-1G signal pattern on
interphase nuclei, suggesting the occurrence of a break point at the vicinity of IRF4/MUM1. Scale bar¼ 5 mm. (b) Metaphase FISH. Metaphases from blood
cells of patient with Se´zary syndrome (case 13). Hybridization of SpectrumGreen-labeled 50 IRF4 probe and the Cyanine3-labeled 30 IRF4 probe
shows a 3-fusion (3F) signal pattern indicating the presence of one extra copy of nonrearranged IRF4 locus. Scale bar¼ 5 mm. (c) Interphase FISH. Skin FFPE
section from case 7. Hybridization of SpectrumGreen-labeled 50 IRF4 probe and Cyanine3-labeled 30 IRF4 probe shows a 4F FISH signal pattern, which indicates
two extra copies of the nonrearranged IRF4 locus. Scale bar¼5 mm. (d–f) Metaphase FISH. Skin tumor cell metaphases obtained from case 1. Scale bar¼ 5 mm.
(d) Hybridization of SpectrumGreen-labeled 50 IRF4 probe and Cyanine3-labeled 30 IRF4 probe shows a 2Fþ 1 G extra signal FISH pattern, indicating that the
break point maps to the 6p25 region within the genomic area corresponding to the RP11-164H16 BAC clone. (e) The green extra signal is localized on the long
arm of chromosome 6 (6q) indicating an inversion. (f) Cyanine3-labeled 30 IRF4 probe. (g–i) FISH, followed by Alexa Fluor 288-labeled anti-CD30
immunostaining on FFPE section of case 1. Scale bar¼5 mm. (g) Global overview at  600 original magnification of an area rich in anaplastic cells showing both
the CD30 membranous staining and FISH signals with some small CD30-negative cells at the upper part. (h) The majority of CD30-positive cells carry IRF4 locus
rearrangements (1F-1R-1G pattern) and CD30-negative cells do not carry IRF4 locus rearrangements (2F pattern, left part). (i) A CD30-positive
cell does not carry IRF4 rearrangement and exhibits a normal 2F signal pattern at the lower part.
Table 1. IRF4 locus alterations in cutaneous T-cell
lymphomas
IRF4 FISH pattern
Diagnosis Normal (%)
IRF4 locus
break point (%)
Extra copies of
nonrearranged
IRF4 locus (%)
C-ALCL (n=23) 16 (69.6) 6 (26) 1 (4.3)
LyP (n=7) 7 (100) 0 (0) 0 (0)
T-MF (n=11) 8 (72.7) 2 (18.2) 1 (9.9)
SS (n=13) 9 (69.2) 0 (0) 4 (30.8)
Total (n=54) 40 (74) 8 (14.8) 6 (11.2)
C-ALCL, cutaneous anaplastic large cell lymphoma; FISH, fluorescence in
situ hybridization; LyP, lymphomatoid papulosis; SS, Se´zary syndrome;
T-MF, transformed mycosis fungoide.
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only 22 and 21% nuclei, which is below the detection
threshold of our array-CGH technique. Moreover, in the
T-MF case with one extra copy of the IRF4 locus detected in
91% nuclei analyzed (case 10), no chromosome 6 gain was
observed by array-CGH, suggesting a global aneuploidy.
FISH analysis of chromosome 6 and ploidy
As shown in Table 4, six cases with extra copies of the IRF4
locus were further analyzed with other FISH probes. In the
patient with C-ALCL (case 7) and in two patients with SS (case
11 and 13), only the 6p region exhibited two and one extra
copies, respectively. For case 11, these data were in
accordance with array-CGH data showing 6p22–6p25 gain.
In three other patients (cases 10, 12, and 14), the extra copies
of the IRF4 locus were found to be a consequence of
polyploidy, as shown in Table 4.
DISCUSSION
In this study, we observed IRF4 locus rearrangements in 6 out
of 23 C-ALCLs (26%) and in 2 out of 11 TMFs (18.2%).
Table 2. CTCLs with abnormal IRF4 FISH pattern
Case Diagnosis Age/sex Site
FISH IRF4 type of
abnormality (% nuclei) CGH array TNM stage1 Follow-up Present status
1 C-ALCL 71/F Skin 2F +1 G extrasignal (60) No imbalance T2aN1M0 NE Alive CR
— Node 2F +1 G extrasignal (64) Alive CR
2 C-ALCL 58/M Skin NA T2bN1M0 NE Alive CR
— Node 1F 1split (85) No imbalance
3 C-ALCL 36/M Skin 1F 1split (39) No imbalance T1aN0M0 NE Alive CR
4 C-ALCL 86/F Skin 1F 1split (54) ND T1aN0M0 NE Alive CR
5 C-ALCL 65/M Skin 1F 1split (55) No imbalance T1aN0M0 NE Alive CR
6 C-ALCL 73/M Skin 1F 1split (88) ND T1aN0M0 Cutaneous relapse
M15
Alive CR
7 C-ALCL 54/M Skin 4F (73) ND T1aN0M0 Regional node
progression M19
NA
— Node NA NA
8 T-MF 72/F Skin 2F+1 G extrasignal (31) No imbalance IIb (T3) Progression Alive PD
9 T-MF 77/F Skin 1F 1split (94) ND III (T4) Progression Died
10 T-MF 78/M Skin 3F (91) No imbalance IIb (T3) Progression DD
11 SS preceded
by MF
67/M Blood 3F (90) 6p22–25 gain III (T4) Progression Alive PD
12 SS 77/F Blood 3F (22) No imbalance III (T4) NE Alive SD
13 SS 64/M Blood 3F (88) ND IVB (T4NxM1B1) Progression Alive PD
14 SS 81/F Blood 3F (21) No imbalance IVA (T4) Progression DD
C-ALCL, cutaneous anaplastic large cell lymphoma; CR, complete remission; DD, died of disease; F, fusion; FISH, fluorescence in situ hybridization;
G, green; NA, not available; ND, not done; NE, no event; PD, progressive disease; SD, stable disease; SS, Se´zary syndrome; TNM, tumor node metastasis;
T-MF, transformed mycosis fungoide.
1At the time of biological sampling.
Table 3. IRF4 or MUM1 immunoreactivity in CD30-positive lymphoproliferations according to the presence of
IRF4 break point
Diagnosis C-ALCL LyP T-MF
Presence of IRF4 break point + n=6  n=13 + n=0  n=7 + n=2  n=4
IRF4 expression
 (o10% cells) 0 1 0 0 0 0
+ (10–50% cells) 0 2 0 1 1 1
++ (50–85% cells) 2 5 0 0 0 1
+++ (485% cells) 4 5 0 6 1 2
Overall positivity1 100% (6/6) 92% (12/13) 0 100% (7/7) 100% (2/2) 100% (4/4)
C-ALCL, cutaneous anaplastic large cell lymphoma; LyP, lymphomatoid papulosis; T-MF, transformed mycosis fungoide.
1Overall positivity percentages did not vary according to the presence of IRF4 break point.
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Neither SS nor LyP showed any IRF4 rearrangement, but
extra copies of the IRF4 locus were detected in 4 out of
13 SS (30.8%), 1 out of 11 T-MF (9.9%), and in 1 out of 23
C-ALCL (4.3%) cases. However, IRF4 protein expression was
observed both in cases with or without IRF4 rearrangement
or extra copy.
So far, no specific chromosomal rearrangement, and
especially translocation or inversion, has been identified as
a recurrent alteration in CTCL. For example, t(2;5)(p23;q35)
translocation or its cytogenetic variants defining ALK-positive
systemic CD30-positive ALCL is not present in CD30-positive
CTCL, although very rare ALK-positive ALCL confined to
the skin has been reported (Beylot-Barry et al., 1998). More
recently, the specific translocation/deletion of the NAV3 gene
at 12q21–q22 identified in patients with MF or SS (Karenko
et al., 2005) was not further confirmed by our study of 24
patients with advanced MF/SS (Marty et al., 2008).
Interestingly, only a small subset of T-cell lymphomas was
shown to display IRF4 locus rearrangements, as only 12 out
of 169 PTCLs exhibited a FISH break-apart signal (Feldman
et al., 2009). Most cases were C-ALCL (8 out of 12), with a
higher prevalence in their C-ALCL group (57%) than in ours
(26%). Moreover, half of the patients with a C-ALCL and an
IRF4 locus rearrangement developed loco-regional nodal
disease during follow-up (Feldman et al., 2009). In our series
of C-ALCL cases included from a dermatological database,
IRF4 locus rearrangements were not found to be predictive of
lymph node involvement, of cutaneous relapse, or of shorter
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Figure 3. Histological, immunophenotypical, and fluorescence in situ hybridization (FISH) aspects of three typical cases with and without IRF4 locus
rearrangement. Left panel: Lymph node section of cutaneous anaplastic large cell lymphoma (C-ALCL) without IRF4 locus rearrangement. (a) Hematoxylin eosin
and safran (HES). Scale bar¼20 mm. (b) Positivity of CD30 immunostaining. (c) Immunostaining shows expression of multiple myeloma antigen 1 (MUM1) by
more than 85% of tumor cells. (d) Normal FISH signal pattern (2F). Scale bar¼ 5 mm. Middle panel: Skin section of case 6 with C-ALCL and IRF4 rearrangement.
(e) HES, 400. (f) Positivity of CD30 immunostaining. (g) Immunostaining shows MUM1 expression by more than 85% of tumor cells. (h) Split FISH signal
pattern (1F-1R-1G). Scale bar¼5 mm. Right panel: Skin section of case 8 with transformed mycosis fungoide and IRF4 locus rearrangement. (i) HES,  400.
(j) Positivity of CD30 immunostaining. (k) Immunostaining shows MUM1 expression by 10–50% of large tumor cells. (l) FISH signal pattern shows an extra
signal of SpectrumGreen-labeled RP11-164H16 (2Fþ 1 G extra signal), indicating that the break point maps to the 6p25 region in the genomic area
corresponding to the RP11-164H16 sequence. Scale bar¼5 mm.
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survival. Inclusion of cases from the hematopathological
department of Feldman et al. (2009) may have led to a
selection of patients referred to their institution because of a
more aggressive disease.
In addition, Feldman et al. (2009) identified four other
cases with an IRF4 rearrangement, with 3 out of 64 PTCL not
otherwise specified, and 1 out of 23 ALK-negative CD30-
positive systemic ALCL cases. Among them, the two
CD30-negative PTCLs were shown to exhibit translocations
between IRF4 and TCR-a loci and might represent a distinct
clinicopathological entity (Feldman et al., 2009). We also
observed that IRF4 locus rearrangements were not specific to
C-ALCL, as they were detected in two out of eight cases of
CD30-positive T-MFs (20%) but in none (0 out of 3) of CD30-
negative T-MF cases. As TCR loci were not involved in IRF4
translocations for C-ALCL cases, different types of non-TCR
partner genes may exist in CD30-positive lymphomas with
IRF4 locus break points (Feldman et al., 2009). Altogether,
non-TCR-mediated IRF4 rearrangements may define another
subgroup of T-cell lymphomas, either systemic or cutaneous,
corresponding to a differentiation or an activation stage, with
a coexpression of CD30 and IRF4 proteins. Our study also
demonstrates that IRF4 locus rearrangements are balanced, as
no IRF4 or 6p25 loss was detected by array-CGH. We also
observed a major breakpoint region encompassing the IRF4
locus between the 30 end of the BAC clone CTD-2308G5 and
the 50 end of the BAC clone RP11-164H16, covering almost
130 kb, and a minor breakpoint region after the 30 end of the
IRF4 coding sequence.
Fluorescence in situ hybridization combined with immuno-
fluorescence assay showed that all cells with IRF4 rearrange-
ments expressed the CD30 antigen, but we also found a
subset of CD30-positive cells that did not harbor such a
rearrangement and exhibited a normal hybridization pattern,
ruling out technical artefacts. From such an observation, it
could be hypothesized that IRF4 locus rearrangements are
secondary genetic events acquired during C-ALCL progres-
sion, and the analysis of sequential samples in the same
patients would help to clarify this question. Indeed, several
well-known oncogenes, such as C-MYC or C-MYB, are
involved in ‘‘driver’’ recurrent primary reciprocal transloca-
tions, involving either IGH or TCR loci as a partner, in well-
defined entities such as Burkitt’s lymphoma or T-cell acute
lymphoblastic leukemia, respectively (Boerma et al., 2009).
The same oncogenes may be involved in a ‘‘passenger’’ or
secondary non-IGH or TCR-mediated rearrangement in other
related entities, such as diffuse large B-cell lymphoma with a
C-MYC rearrangement (Dave et al., 2006) or T-cell acute
lymphoblastic leukemia with a C-MYB duplication (Clappier
et al., 2007). IRF4 locus rearrangements with non-TCR
partner gene(s) need therefore to be investigated by the
characterization of molecular break point(s), as well as by its
clinical consequences on larger series.
We further identified extra copies of the IRF4 locus in all of
the most common CTCL subtypes: 4 out of 13 SS (30.8%), 1
out of 11 T-MFs (9.9%), and 1 out of 23 C-ALCLs (4.3%).
Compilation of FISH analysis and array-CGH data led us to
identify in three cases a partial 6p gain (6p22–p25 in case 11
as determined in array-CGH), and a chromosome 6 trisomy
in the three other cases. In the latter, global hypotetraploidy
or triploidy was observed in two cases and chromosome 6
trisomy in the last case. Altogether, our data suggest that the
presence of an IRF4 extra copy results from global aneuploidy
or chromosomal instability distinct from IRF4-specific gain or
amplification.
Moreover, the two CD30-positive T-MF cases with an IRF4
locus rearrangement exhibited histological lesions resembling
C-ALCL, but occurring in the course of MF, and were therefore
considered as large cell transformation after a multidisciplin-
ary review. In view of our findings, T-MF cases exhibiting an
IRF4 rearrangement should be reevaluated not only at the
clinicopathological level but also with genome-wide ana-
lyses, such as array-CGH, to define whether they share the
cytogenetic profile of either T-MF or C-ALCL. Finally, the
presence of IRF4/MUM1 gene rearrangements led us to define
a CD30-positive subgroup of cutaneous T-cell lymphoma of
C-ALCL and borderline CD30-positive T-MF cases.
As in the study by Feldman et al. (2009), IRF4 immuno
staining pattern was not found to predict the presence of IRF4
rearrangement. Kempf et al. (2008) suggested that IFR4
Table 4. Cases exhibiting extra copies of nonrearranged IRF4 locus—compilation of chromosome 6 and ploidy
analysis by different techniques
Case Diagnosis FISH IRF4 (%)
FISH analysis of
ploidy (%)
FISH 6p25- CEP6-
6q23–11q13
(number of spots) Chr 6 CGH array profile Conclusion
7 C-ALCL 4F (73) ND 4-2-2-2 ND 6p partial gain
10 T-MF 3F (91) Hypotetraploidy (50) 3-3-3-3 No imbalance Hypotetraploidy
Chr. 6 trisomy
11 SS 3F (90) Normal 3-2-2-2 6p22–25 gain 6p22–25 gain
12 SS 3F (22) Triploid (24) 3-3-3-3 No imbalance Triploidy
13 SS 3F (80) ND 3-2-2-2 ND 6p partial gain
14 SS 3F (21) Normal 3-3-3-2 No imbalance Chr. 6 trisomy
C-ALCL, cutaneous anaplastic large cell lymphoma; CGH, comparative genomic hybridization; F, fusion; FISH: fluorescence in situ hybridization; ND, not
done; SS, Se´zary syndrome; T-MF, transformed mycosis fungoide.
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expression may be a valuable tool for the distinction between
LyP and C-ALCL. In accordance with others (Wasco et al.,
2008; Benner et al., 2009; Hernandez-Machin et al., 2009),
we found that IRF4 protein is strongly expressed in LyP,
C-ALCL, and T-MF cases and could not be used in their
differential diagnosis. Although most MMs do not have
genetic lesions in the IFR4 locus, the IRF4 expression
observed is strongly correlated with C-MYC expression in a
positive regulatory loop (Shaffer et al., 2008). CD30, a
member of the tumor necrosis factor family, also expressed in
MM, activates both the canonical and alternative NF-kB
pathways in ALCL cells, regardless of the presence of NPM-
ALK (Wright et al., 2007; Hirsch et al., 2008). As NF-kB
pathway activation upregulates IRF4 expression in a subset of
B- or T-cell lymphomas (reviewed by Shaffer et al. (2009)), it
could be hypothesized that both CD30 and IRF4 could act
synergistically in CTCL expressing both proteins. Interest-
ingly, the expression of TRAF1, a cytoplasmic protein
involved in canonical NF-kB activation and CD30-induced
alternative NF-kB activation in Hodgkin’s lymphoma cells
(Guo et al., 2009), is closely associated with the expression of
IRF4 and CD30 in C-ALCL, T-MF, and LyP (Benner et al.,
2009).
Whether IRF4, CD30, or NF-kB might individually or in
combination represent therapeutic targets in IRF4-positive
CTCL needs to be further evaluated in view of the competing
effects triggered by CD30 stimulation alone in ALCL cells
(Hirsch et al., 2008). Knockdown of IRF4 by RNA inter-
ference induced a rapid nonapoptotic cell death in MM cells,
regardless of the presence of IRF4 rearrangement and NF-kB
activation (Shaffer et al., 2009). The proteasome inhibitor,
bortezomib, which downregulates constitutive NF-kB activa-
tion in CTCL, has been shown to induce cell death in several
CTCL cell lines and in primary cells from Se´zary patients (Sors
et al., 2006; Kiessling et al., 2009). In the HUT-78 Se´zary cell
line, bortezomib induces a downregulation of PRDM1b, a
transcriptional repressor also required for terminal B-cell
differentiation into plasma cells, followed by IRF4 and
C-MYC downregulation (Zhao et al., 2008). Although
bortezomib has been reported as a single effective agent in
previously pretreated 10 MF patients (Zinzani et al., 2007),
recent biological data show that more specific inhibitors of
NF-kB activation or iron metabolism would be more efficient
in inducing CTCL nonapoptotic cell death (Kiessling et al.,
2009).
A further demonstration of IRF4 dependency or addiction
of CTCL cells for their survival and the characterization of
IRF4 break points in a subset of CD30-positive CTCLs will
also help to decipher these pathways, which interestingly
seem to be shared by MM, cutaneous, and systemic CD30-
positive lymphomas.
MATERIALS AND METHODS
Case selection
Cases were retrieved from the Aquitaine database of cutaneous
lymphoma. The study was performed after obtaining informed
written consent from patients according to the Declaration of
Helsinki Principles and was approved by the medical ethical
committee of Aquitaine and CHU de Bordeaux. Clinicopathological
diagnosis (Swerdlow et al., 2008) and tumor node metastasis staging
corresponded to the time of biological sampling (Willemze et al.,
2005; Kim et al., 2007; Olsen et al., 2007). To investigate samples
with a high tumor cell content, we retrieved 60 patients from our
files (53 patients with CTCL and 7 patients with LyP), with dense
lymphoid infiltrates. Sixty-one samples that matched to 54 patients
gave informative results (23 C-ALCL patients, 11 T-MF, 13 SS, and 7
LyP) by FISH. Patients with C-ALCL presented at the time of the study
with cutaneous nodule or tumor, and with dense dermal large cell
infiltrate with anaplastic, pleomorphic, or immunoblastic morphol-
ogy, with more than 75% of tumor cells expressing the CD30
antigen. These patients had no history of MF. Five patients with
C-ALCL had a regional lymph node involvement at the time of
sampling and three other patients had a secondary regional lymph
node involvement. The 11 patients with T-MF were at an advanced
stage of the disease (T3 or T3–4), with a large tumor cell skin infiltrate
that often expressed the CD30 antigen (8 out of 11 cases) in more
than 50% of large tumor cells. Two of these T-MF cases had
metastatic involvement (M1 stage). Among the 13 patients with SS, 3
had secondary SS according to Olsen et al. (2007), and one had T-
SS. From all patients, 67 samples were analyzed corresponding to 49
skin samples (11 T-MF and 38 C-ALCL), 13 blood samples (13 SS), 4
lymph node samples (4 C-ALCL), and 1 bone marrow sample
(1 T-MF).
Cell culture and metaphase spread
In 13 patients with SS, the presence of an elevated lymphocyte count
(above 10,000 cells ml1) with hyper convoluted cerebriform nuclei
(at least above 1,000 cells ml1) prompted us to culture blood cells
according to standard protocols (Verma and Babu, 1995). In three
patients with C-ALCL and in one patient with T-MF, cells dissociated
from skin tumors were cultured for 72 hours according to our
published protocol (Chevret et al., 2006). In one patient with T-MF
with bone marrow involvement, culture of bone marrow cells was
performed.
Fluorescence in situ hybridization
IRF4 locus-specific FISH. Nuclei preparation (n¼ 23) and 3 mm
tissue sections (n¼ 17) were obtained from FFPE material. Skin or
lymph node touch imprints (n¼ 9) were obtained from frozen
material. Cytogenetic pellets from skin, blood, or bone marrow
samples were also analyzed. Samples were hybridized according to
our established protocols (Marty et al., 2008).
To establish a break-apart FISH strategy with dual-color probes
flanking the IRF4 locus, BAC clones were identified using
the University of California at Santa Cruz Genome Browser
(http://www.genome.UCSC.edu) and were ordered from Invitrogen
(Cergy, France). A plasmid 6 pericentromeric probe pEDZ6 (gift from
Dr Rocchi, www.biologia.uniba.it/rmc/) was used as control. BACs
were amplified in bacteria (Escherichia coli) and DNA was isolated
using a Plasmid Maxi Kit (QIAGEN, Courtaboeuf, France). BAC
DNA probes were labeled with appropriate fluorochromes
(SpectrumGreen-dUTP, Cyanine3-dUTP) using a Nick Translation
Kit (Vysis/Abbott molecular, Rungis, France). Probes were hybri-
dized with the pericentromeric 6 control probe on healthy donor
metaphases. Their 50 and 30 ends were sequenced using consensus
primers and their identity was checked using the Blast Program of the
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National Center for Biotechnology Information (NCBI) (http://
ncbi.nlm.nih.gov/blast). These control experiments led us to discard
two BAC clones (CTD-2314K17 and RP11-119L15) located on the 50 of
IRF4 and the BAC clone (CTD-3052J12) covering the IRF4 locus, which
showed nonspecific hybridization to the short arm of chromosome 16
(16p). Such nonspecific signals also provided false extra signals on
interphase nuclei (four signals per nucleus). After these controls, two
probes were validated: the 50 IRF4 CTD-2308G5 probe was labeled with
Cyanine3 (R for red) and the 30 IRF4 RP11-164H16 probe was labeled
with SpectrumGreen (G for green). After hybridization of 50 and 30 IRF4
probes, the normal diploid pattern was two fusion signals (2F), whereas a
chromosomal break point at the vicinity of IRF4 would theoretically
provide a typical 1F-1R-1G pattern (1F-1 split), suggesting the occurrence
of a translocation in this genomic area. An extra copy of the IRF4 locus,
due to either 6p gain or chromosome 6 polysomy, would provide a
(2þ n)F pattern (see Figure 1b).
All FISH patterns were recorded by analyzing 100 non-overlapped
nuclei by two independent observers (APL and MPC), and a mean score
was determined. All individual patterns were scored and taken into
account when their individual percentage exceeded a 5% threshold.
FISH analysis of chromosome 6. Available samples exhibiting
extra copies of a nonrearranged IRF4 locus were studied with LSI
RREB1/LSI MYB/LSI CCND1/CEP 6 probes (Vysis/Abbott molecular),
which contain a multicolor mixture of probes hybridizing to 6p25/
6q23/11q13/cen 6, according to the manufacturer’s protocol.
FISH analysis of ploidy. We also investigated the ploidy of four
samples carrying extra copies of nonrearranged IRF4 locus.
Chromosomes 5, 9, and 15 were analyzed with LSI D5S23/
D5S721, CEP 9, and CEP15 multicolor probe set (Vysis/Abbott
molecular). Tumor samples were considered to contain a significant
proportion of triploid or tetraploid cells when more than 20% of cells
presented a chromosome number abnormality.
FISH combined with anti-CD30 immunostaining. To further
characterize cells carrying IRF4 rearrangements, we performed IRF4
locus-specific FISH, followed by immunostaining with a CD30
antibody on FFPE tissue sections. After dewaxing and rehydration of
FFPE tissue sections, permeabilization of membrane structures was
performed by incubating samples in Triton 0.5%. A heat pretreat-
ment in a pressure cooker in a pH 6 10mM citric acid solution was
carried out for 10minutes at full pressure. The pressure cooker was
then depressurized using running tap water. Thereafter, slides were
dehydrated and denatured in 70% formamide/2 standard saline
citrate at 72 1C for 5minutes before hybridization with previously
denaturated IRF4 probes. After a short wash in 2 standard saline
citrate/0.3% NP40, prewarmed at 72 1C for 2minutes, immunostain-
ing was performed. After pretreatment with a 5% fetal bovine serum
solution to block nonspecific-binding sites, the primary monoclonal
mouse anti-human CD30 antibody (BerH2, DAKO, Trappes, France,
1/25 dilution) was incubated overnight in a humidified chamber at
4 1C. After three successive 5-minutes washes with phosphate-
buffered saline, the slides were incubated for 1 hour with a
secondary antibody (AlexaFluor 488-labeled anti-mouse antibody,
Invitrogen 1/400 dilution, Invitrogen) at room temperature in a humi-
dified chamber. Finally, the slides were mounted with 4,6-diamidino-
2-phenylindole and analyzed by fluorescence microscopy.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were incubated in
pretreatment buffer for antigen retrieval and were then reacted with
monoclonal mouse anti-human CD30 (BerH2; DAKO) and IRF4
(clone MUM1p; DAKO) antibodies for 30minutes. Immunoreaction
was detected using the LSAB protocol (DAKO). CD30 and MUM1
immunostaining was performed in 19 cases of C-ALCL, as well as in
7 LyPs and 6 T-MFs. A membranous stain with or without
cytoplasmic labeling was considered as positive for CD30. A
positive MUM1 staining was defined as a nuclear labeling in more
than 10% of large infiltrating cells. Immunostaining for MUM1 was
semiquantitatively scored as follows: , no, oro10% of large tumor
cells stained; þ , 10–50% of large tumor cells stained; þ þ , 50–85%
of large tumor cells stained; and þ þ þ ,485% of large tumor cells
stained. The intensity was not scored independently, as it was found
to correlate with the percentage of labeled cells.
Chromosome 6 array-CGH profile
Array-CGH experiments were performed according to standard
procedures (Orsetti et al., 2006; Marty et al., 2008) on 3113 BACs
Integrachip arrays (ie., 3K arrays) produced by IntegraGen, (Evry,
France) and obtained through ArrayGenomics (Voisins le Breton-
neux, France). Hybridization, scanning, normalization, and data
analysis were performed at the Bergonie´ Institute CGH array facility
using GenepixPro 4.0 (Molecular Devices, St Gre´goire, France). Files
were normalized using the Curie Institute VAMP tool (La Rosa et al.,
2006) through the CAPweb bioinformatics platform (Liva et al.,
2006) (http://bioinfo-out.curie.fr/CAPweb/). Analyses were retained
if more than 90% of BAC clones presented a good signal-to-noise
ratio (signal-to-noise ratio of at least 3).
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